Company overview
Basic information
Company name
Inovexa, MB
Company code
306328188
VAT code
LT100016121312
Registered address
Vilnius, Perkūnkiemio g. 19, LT-12120
Registration date
2023-05-29
Company age: 3 y. 5 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Other computer programming activities
Ownership form
Private without foreign capital
MB Inovexa
Company code: 306328188
Address: Vilnius, Perkūnkiemio g. 19, LT-12120
VAT code: LT100016121312
Description
This description was generated by artificial intelligence.
Inovexa, MB (company code 306328188) is an operational private small partnership registered on 29 May 2023. It belongs to the sector of national private non-financial companies and is classified as a micro-sized business. The company is privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. Governance is CEO only. Its registered address is Perkunkiemio g. 19, Vilnius, Vilniaus m. municipality, Vilnius County. The company’s main activity is EVRK K.62.10.90, Other computer programming activities.
Financially, Inovexa generated EUR 45.3K in revenue in 2025, slightly above EUR 44.7K in 2024 and EUR 22.8K in 2023, which covered a shorter 216-day period. Net profit was EUR 6.2K in 2025, close to EUR 6.2K in 2024 and EUR 11.6K in 2023. The profit margin was 13.7% in 2025, compared with 13.9% in 2024 and 51.1% in 2023. At the end of 2025, equity stood at EUR 6.3K, liabilities at EUR 4.7K, and total assets at EUR 11.0K. The company’s equity ratio was 56.9%, with debt to equity at 0.76 and asset turnover at 4.12x. Staff data is tracked so far in 2026.
Financially, Inovexa generated EUR 45.3K in revenue in 2025, slightly above EUR 44.7K in 2024 and EUR 22.8K in 2023, which covered a shorter 216-day period. Net profit was EUR 6.2K in 2025, close to EUR 6.2K in 2024 and EUR 11.6K in 2023. The profit margin was 13.7% in 2025, compared with 13.9% in 2024 and 51.1% in 2023. At the end of 2025, equity stood at EUR 6.3K, liabilities at EUR 4.7K, and total assets at EUR 11.0K. The company’s equity ratio was 56.9%, with debt to equity at 0.76 and asset turnover at 4.12x. Staff data is tracked so far in 2026.
Download a detailed company report
Make confident decisions with all the information about Inovexa, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.